The role of extended treatment discussed by mastitis experts

‘The benefit of extended therapy for mastitis, myth or fact?’ was the topic at the third global milk quality expert forum, held on 16-17 January in Barcelona and organised by Boehringer Ingelheim. The forum was attended by 15 milk quality experts from 13 different countries, which allowed for an excellent interaction between participants and speakers.

When to consider extended treatment
Extended antibiotic treatment of Streptococcus uberis and Staphylococcus aureus mastitis significantly increases clinical and bacteriological cure rates, according to scientific data. However, extended therapy also has its limitations. While risk factors (e.g. age of cow, number of colonies, somatic cell count) need to be taken into account, the added costs of labour, antibiotics and an
increased milk withdrawal time might not balance out the gain obtained with cure. But most importantly, participants agreed that extended treatment cannot be considered judicious use of
antibiotics if used as blanket treatment of all clinical or subclinical mastitis cases, and should only be implemented case-by-case.

The importance of treating first-time mastitis cases
What is the aim of treating mastitis: a bacteriological cure or prevention of recurrence? According to unpublished data, nearly one half (43%) of all clinical mastitis cases are recurrent cases.
And of all recurrent cases, only 10% are ‘true’ persistent infections with the same strain, suggesting that tissue damage, genetic predisposition and environmental factors play an important role.
Mastitis treatment should therefore focus on prevention and thorough treatment of first-occurrence cases. Results of a study showed that intensive treatment of first-time mastitis cases may
help prevent recurrence.

The microbiome of milk
DNA sequencing of milk shows that healthy quarters have a greater microbial diversity than quarters with clinical mastitis. Milk is full of bacterial organisms, of which many anaerobic organisms that don’t appear on normal culture. However, pathogenssuch as Escherichia coli and Klebsiella spp. were only found in the milk microbiome if they showed up on conventional aerobic culture. On the other hand, S. uberis seems to be part of the healthy microbiome, and was present in small quantities in all culture-negative mastitis samples. Intramammary treatment studies with a broad-spectrum antibiotic showed no real impact on microbial diversity of the microbiome. The hypothesis was raised that narrow-spectrum treatment may lead to a microbiome imbalance, thus indirectly contributing to mastitis.

Treatment protocols in human medicine
A medical doctor presented data on mastitis treatment in women, for which standard antibiotic treatment is usually prescribed for 10 to 14 days – much longer than the so-called ‘extended’ veterinary treatment. In spite of the lack of evidence for the length of treatment, the message to the general public usually is to ‘finish the course of antibiotics to avoid antimicrobial resistance’. While the duration of treatment depends on the type of infection and severity, symptom resolution was found to be a good indicator. In human medicine, apps are now being developed allowing patients to report a clinical cure, providing feedback on the duration of clinical signs.

Managing the farmer’s fears
Since human behaviour and perception is an important parameter to take into account, the group also discussed communication of scientific evidence to farmers. It was suggested that, as farmers
are often unsure about the effect of treatment, they may consider extended antibiotic treatment as ‘good stockmanship’. And if the evidence – e.g. the veterinarian’s scientific advice – is at odds
with their own experience, they will disregard the advice. Farmers prefer to treat as long as symptoms are visible: ‘Better safe than sorry’. Communication on effective treatment is essential, and
veterinarians should learn to manage the farmer’s fears rather than facts.


Oriol Franquesa, Spain (Chair); Nabeela Mughal, UK (speaker, Imperial College London); Ian Hodge, New Zealand; Elke Abbeloos (Boehringer Ingelheim); Camilo de Mendonca (Boehringer Ingelheim); Jolanda Jansen, The Netherlands (speaker, St Anna Advies);Giacomo Tolasi, Italy; Michael Farre, Denmark; Jean-Philippe Roy, Canada (speaker, University of Montreal); Olivier Salat, France; Bill May, UK; Marcos Veiga, Brasil; Christian Scherpenzeel, The Netherlands (speaker, GD Deventer); Martin Pol, Argentina; Sarne De Vliegher (Belgium); Tine van Werven (The Netherlands).